Showing results (21-30 of 57) with videos related to
Sort By:
Pageof 6
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 8, 2017
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted TherapiesJody C Chuang, Henning Stehr, Ying Liang, et al.Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancerJessica A Hellyer, Henning Stehr, Millie Das, et al.JCO Clinical Cancer Informatics|July 15, 2021
Machine Learning Radiomics Model for Early Identification of Small-Cell Lung Cancer on Computed Tomography ScansRajesh P Shah, Heather M Selby, Pritam Mukherjee, et al.Clinical Lung Cancer|June 26, 2022
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based RegimensSarah Waliany, Heather Wakelee, Kavitha Ramchandran, et al.Cancer Chemotherapy and Pharmacology|July 22, 2018
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignanciesMillie Das, Sukhmani K Padda, Adam Frymoyer, et al.Cancer Treatment and Research Communications|May 16, 2020
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORSJonathan W Riess, Nadine S Jahchan, Millie Das, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2021
Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLCSarah Waliany, Han Zhu, Heather Wakelee, et al.Clinical Lung Cancer|November 28, 2021
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung CancerJessica A Hellyer, Maya N White, Rebecca M Gardner, et al.JTO Clinical and Research Reports|November 19, 2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and OutcomesSurbhi Singhal, Caressa Hui, Joel W Neal, et al.JTO Clinical and Research Reports|May 21, 2026
Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914]Surbhi Singhal, Caressa Hui, Joel W Neal, et al.Pageof 6